Cargando…

Mechanism of Yangxinshi Intervention on Cardiac Fibrosis in Diabetic Cardiomyopathy Based on Network Pharmacology

BACKGROUND: Cardiac fibrosis (CF) is major myocardial change in diabetic cardiomyopathy (DCM). Yangxinshi as a Chinese medicine formula is used to treat cardiovascular diseases. However, the exact effective mechanism of Yangxinshi on CF is still uncertain. Hence, based on the pharmacological network...

Descripción completa

Detalles Bibliográficos
Autores principales:	Kuang, Jiangying, Wu, Kaiyi, Li, Wenjing, Zhang, Xuguang, Zhang, Hao, Jia, Zhiyi, Han, Qingmei, Tian, Xiaochen, Sun, Rong, Lu, Qinghua, Liu, Yusheng
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Hindawi 2022
Materias:	Research Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8799326/ https://www.ncbi.nlm.nih.gov/pubmed/35096111 http://dx.doi.org/10.1155/2022/3968494

Ejemplares similares

Effects of Yangxinshi tablet on exercise tolerance in patients with coronary heart disease: A protocol of randomized, double-blind, placebo-controlled, and multi-center trial
por: Zhang, Sisi, et al.
Publicado: (2020)

Saxagliptin protects against diabetic nephropathy by inhibiting caspase 3/PARP-1-dependent nephrocyte apoptosis
por: Xing, Xiaowei, et al.
Publicado: (2021)

Central role of cardiac fibroblasts in myocardial fibrosis of diabetic cardiomyopathy
por: Cheng, Yanan, et al.
Publicado: (2023)

FTZ Ameliorates Diabetic Cardiomyopathy by Inhibiting Inflammation and Cardiac Fibrosis in the Streptozotocin-Induced Model
por: Wang, Lexun, et al.
Publicado: (2021)

Identification of target genes in cardiomyopathy with fibrosis and cardiac remodeling
por: Zhao, Jianquan, et al.
Publicado: (2018)

Case report: A case of hypocalcemic cardiomyopathy with non-reversible cardiac fibrosis
por: Xie, Ying, et al.
Publicado: (2023)

Long noncoding RNA Crnde attenuates cardiac fibrosis via Smad3‐Crnde negative feedback in diabetic cardiomyopathy
por: Zheng, Dezhi, et al.
Publicado: (2019)

Activation of PPARα Ameliorates Cardiac Fibrosis in Dsg2-Deficient Arrhythmogenic Cardiomyopathy
por: Qiu, Zirui, et al.
Publicado: (2022)

Renal Denervation Findings on Cardiac and Renal Fibrosis in Rats with Isoproterenol Induced Cardiomyopathy
por: Liu, Qian, et al.
Publicado: (2015)

CXCR4 Antagonism Reduces Cardiac Fibrosis and Improves Cardiac Performance in Dilated Cardiomyopathy
por: Chu, Po-Yin, et al.
Publicado: (2019)

Traditional Chinese medicine baoxin decoction improves cardiac fibrosis of rats with dilated cardiomyopathy
por: Sun, Rongrong, et al.
Publicado: (2017)

The Impact of Trimetazidine on Cardiac Fibrosis, Inflammation, and Function in Ischemic Cardiomyopathy Patients
por: El-khodary, Noha M., et al.
Publicado: (2022)

Pharmacological inhibition of MDM4 alleviates pulmonary fibrosis
por: Mei, Qianru, et al.
Publicado: (2023)

Editorial: Cardiac Hypertrophy: From Compensation to Decompensation and Pharmacological Interventions
por: Liu, Ya, et al.
Publicado: (2021)

Matrine suppresses cardiac fibrosis by inhibiting the TGF-β/Smad pathway in experimental diabetic cardiomyopathy
por: Zhang, Yong, et al.
Publicado: (2018)

Cardiac fibrosis and dysfunction in experimental diabetic cardiomyopathy are ameliorated by alpha-lipoic acid
por: Li, Chun-jun, et al.
Publicado: (2012)

The Role of Cardiac Fibrosis in Diabetic Cardiomyopathy: From Pathophysiology to Clinical Diagnostic Tools
por: Pan, Kuo-Li, et al.
Publicado: (2023)

Pharmacological Intervention in Hepatic Stellate Cell Activation and Hepatic Fibrosis
por: Schon, Hans-Theo, et al.
Publicado: (2016)

Predictive Values of N-Terminal Pro-B-Type Natriuretic Peptide and Cardiac Troponin I for Myocardial Fibrosis in Hypertrophic Obstructive Cardiomyopathy
por: Zhang, Changlin, et al.
Publicado: (2016)

Opposite Effects of Gene Deficiency and Pharmacological Inhibition of Soluble Epoxide Hydrolase on Cardiac Fibrosis
por: Li, Lijuan, et al.
Publicado: (2014)

Identification of fibrosis in hypertrophic cardiomyopathy: a radiomic study on cardiac magnetic resonance cine imaging
por: Pu, Cailing, et al.
Publicado: (2022)

Forskolin Protected against Streptozotocin-Induced Diabetic Cardiomyopathy via Inhibition of Oxidative Stress and Cardiac Fibrosis in Mice
por: Zhang, Xu, et al.
Publicado: (2021)

Myocardial fibrosis in desmin-related hypertrophic cardiomyopathy
por: He, Yi, et al.
Publicado: (2010)

Exercise related ventricular arrhythmias are related to cardiac fibrosis in hypertrophic cardiomyopathy mutation carriers
por: van Rijsingen, I. A. W., et al.
Publicado: (2011)

Efficacy of Novel Noncontrast Cardiac Magnetic Resonance Methods in Indicating Fibrosis in Hypertrophic Cardiomyopathy
por: Sharifian, Maedeh, et al.
Publicado: (2021)

Exploring metabolism in scleroderma reveals opportunities for pharmacological intervention for therapy in fibrosis
por: Cantanhede, Isabella Gomes, et al.
Publicado: (2022)

Lack of Relationship between Fibrosis-Related Biomarkers and Cardiac Magnetic Resonance-Assessed Replacement and Interstitial Fibrosis in Dilated Cardiomyopathy
por: Rubiś, Paweł, et al.
Publicado: (2021)

An Integrative Pharmacology-Based Strategy to Uncover the Mechanism of Zuogui Jiangtang Shuxin Formula in Diabetic Cardiomyopathy
por: Huang, Yalan, et al.
Publicado: (2023)

Pharmacological Inhibition of Serine Proteases to Reduce Cardiac Inflammation and Fibrosis in Atrial Fibrillation
por: Coppini, Raffaele, et al.
Publicado: (2019)

Unveiling the Vital Role of Long Non-Coding RNAs in Cardiac Oxidative Stress, Cell Death, and Fibrosis in Diabetic Cardiomyopathy
por: Tian, Yuan, et al.
Publicado: (2022)

Antioxidative Effects of Natural Products on Diabetic Cardiomyopathy
por: Yan, Bingdi, et al.
Publicado: (2017)

Cannabinoid 1 Receptor Promotes Cardiac Dysfunction, Oxidative Stress, Inflammation, and Fibrosis in Diabetic Cardiomyopathy
por: Rajesh, Mohanraj, et al.
Publicado: (2012)

Circulating miRNAs as Potential Biomarkers Associated with Cardiac Remodeling and Fibrosis in Chagas Disease Cardiomyopathy
por: Nonaka, Carolina Kymie Vasques, et al.
Publicado: (2019)

SARC Gene Mutation Is Associated With Myocardial Fibrosis Measured by Histopathology and Cardiac Magnetic Resonance in Patients With Hypertrophic Cardiomyopathy
por: Huang, Manyun, et al.
Publicado: (2023)

Molecular mechanism of Danshenol C in reversing peritoneal fibrosis: novel network pharmacological analysis and biological validation
por: Liang, Jiabin, et al.
Publicado: (2023)

T(1) mapping for characterization of myocardial fibrosis in hypertrophic cardiomyopathy
por: Liu, Ying, et al.
Publicado: (2016)

Rapamycin Attenuates Cardiac Fibrosis in Experimental Uremic Cardiomyopathy by Reducing Marinobufagenin Levels and Inhibiting Downstream Pro‐Fibrotic Signaling
por: Haller, Steven T., et al.
Publicado: (2016)

Pharmacology of fibrosis and tissue injury
por: Chvapil, Milos
Publicado: (1974)

Metabolic and Cardiac Adaptation to Chronic Pharmacologic Blockade of Facilitative Glucose Transport in Murine Dilated Cardiomyopathy and Myocardial Ischemia
por: Heitmeier, Monique R., et al.
Publicado: (2018)

NOX1 promotes myocardial fibrosis and cardiac dysfunction via activating the TLR2/NF-κB pathway in diabetic cardiomyopathy
por: Zhang, Dandan, et al.
Publicado: (2022)

Cannot write session to /tmp/vufind_sessions/sess_vh0ue56ed925utatqjhl42tufr